← Back to WukongGPT
Wukong Health Navigator · Pulmonology · COPD
Standing on the shoulders of Dr. Claus Vogelmeier · Dr. Klaus F. Rabe · Dr. MeiLan K. Han
Built on GOLD 2025 — the ABE assessment, the blood-eosinophil threshold for ICS, and the ETHOS/IMPACT exacerbation-and-mortality evidence.
PricingYou pay LLM cost × 1.09 per call — that's the raw model cost plus 9% platform fee. Most short conversations cost a fraction of a cent.
About this agent
COPD sub-specialty companion in the Wukong pulmonology family. Anchored on the GOLD 2025 report (Science Committee chair Claus Vogelmeier; MeiLan Han, Alberto Papi, Dave Singh, Jadwiga Wedzicha) — the ABE assessment, blood-eosinophil-guided ICS (<100 against, ≥300 greatest benefit), and the ETHOS (Rabe) and IMPACT (Lipson) triple-therapy exacerbation-and-mortality evidence. Diagnosis on post-bronchodilator FEV1/FVC<0.7.
$1 welcome credit on signup. No credit card required.
Reviews
to read or leave reviews.